AIDS-Like Disease Mysteriously Appears Where Merck Conducted Vaccine Trials
Aug 28, 2012 | Susanne Posel
In Southeast Asia, specifically Thailand, an AIDS-like “virus” has
been found in people that are not infected with HIV. Those infected have
their immune-system compromised. Health officials say that this new
AIDS “virus” is not contagious, which begs the question: how did these
people come down with this new strain of AIDS?
This infection does not spread the same as AIDS does, according
to Dr. Sarah Browne, scientist with the National Institutes of Health
(NIH) National Institute of Allergy and Infectious Diseases. Browne led
the team of researchers in Thailand and Taiwan where the disease made
its first appearance.
The disease appears to be directed at people of Asian descent; even those living in the US.
Browne has concluded that the new AIDS causes those infected to
produce autoantibodies that block interferon-gamma, a chemical signal
that assists the human body in fighting infections. The new AIDS targets
this chemical and leaves the victim unable to fight off any infection –
leaving the person vulnerable to developing deadly sicknesses from even
the common cold.
Browne is touting this new AIDS as “adult-onset” because “we do not know what’s causing [people] to make these antibodies.”
In 1962, the US Senate received a report
concerning chemical and biological warfare. This is the government
contract where HIV-like and Ebola-like viruses were bio-engineered by
the US military and the bioweapons contracting lab Biomedics. They were
producing viral cancer in monkeys that could then be used through
genetic engineering to infect humans.
Robert Gallo, working with the National Cancer Institute, was part of
this project. Millions of people are dying from this US sponsored
government project to depopulate certain groups of people because of
their ethnic heritage; and the US Congress knew about it, and endorsed
Scientific teams from various institutions like the Scripps Research
Institute, the Rockefeller University, NIAID’s Vaccine Research Center
and Duke University are closely following how they can use the human
body’s immune system against the array of HIV strains that keep popping
In the sub-Saharan region of Africa, drug resistant forms of HIV are being found which leave current treatments ineffective.
HIV vaccine trials conducted by Merck in 2007
actually made those who took the vaccine more susceptible to the
disease. Then in 2009, human experiments in Thailand pointed to drug
corporations toward a powerful vaccine that utilized immune system
generated anti-bodies as the answer to their dilemma.
New vaccines focus on tricking the human body to reject the HIV/AIDS
virus by manipulating the immune system. This mutation is suspected to
be able to assist the human body in identifying and neutralizing the
The pharmaceutical giant Merck, along with the US Military HIV
Research Program has been attempting to pioneer the HIV vaccine industry
with trials in 2007. This has prompted the study into the human immune
system and how to effectively manipulate its functions.
Merck are returning to Thailand and the scene of their human
experiments in 2007 to trial study a new HIV immunization that will
combine two separate vaccines. Johnson&Johnson are joining with
Merck, the National Institutes of Medicine and other bio-technological
corporations that specialize in researching the viral effects of
genetically engineered viruses on the human and animal immune system.
from the Gates Foundation, Wellcome Trust, National Institutes of
Health and the European Union, HIV research and studies into vaccines
will be able to have assistance from groups like the Global HIV Vaccine
According to an annual volume of the Special Cancer Virus Program , human experimentation with cancer-causing and immunosuppressive viruses is essential.